ArticleCancer genomics & proteomics
Clinical and Functional Significance of p38δ (MAPK13) in Lung Cancer.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimMAPK13 (p38δ) is a frequently identified but often ignored MAP kinase in epithelial gene signatures. This study aimed to characterize p38δ expression in normal and cancerous epithelial tissues, investigate its possible role in epithelial identity, epithelial-mesenchymal transition (EMT), cancer progression, drug resistance, and evaluate its prognostic value. MATERIALS AND
methodsQuantitative analysis assessed p38δ expression across diverse normal human epithelial tissues and correlated it with epithelial markers in cancer cell lines. A p38δ gene signature was analyzed for pathway enrichment in epithelial processes. p38δ expression was compared between epithelial and mesenchymal lung cancer models and in EGFR inhibitor-resistant cells. Prognostic data on cancer patient survival was collected for various cancer types. Functional studies included p38δ knockdown to evaluate EMT markers, E-cadherin/EpCAM, Vimentin and proliferation, and exogenous p38δ expression to assess cell growth/migration. p38δ mRNA and protein levels were measured in Osimertinib-resistant cell lines.
resultsp38δ was predominantly expressed across diverse normal epithelial tissues and correlated strongly with epithelial markers in cancer cells. Its gene signature enriched pathways vital for epithelial architecture, adhesion, and differentiation. p38δ was consistently higher in epithelial-enriched lung cancer models and suppressed in EGFR inhibitor-resistant cells. Prognostic impact was context-dependent: high expression correlated with favorable overall survival in ovarian, lung, and rectum cancers, but inversely with outcomes in liver, breast, and pancreatic cancers. Functionally, p38δ knockdown induced EMT and increased proliferation. Conversely, exogenous p38δ suppressed cell growth/migration. Crucially, acquired Osimertinib resistance consistently corresponded with significant reductions in p38δ levels.
conclusionp38δ is a critical marker and regulator of epithelial identity. Its dysregulation and loss are systematically linked to EMT and drug resistance in cancer. Given its complex, context-dependent prognostic value and functional significance, p38δ holds significant potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.